NHS National Generic Pharmaceuticals Wave 13
The NHS Commissioning Board (operating under the name of NHS England) · Awarded
- Buyer
- The NHS Commissioning Board (operating under the name of NHS England)
- Status
- Awarded
- Country
- United Kingdom
- Region
- England
- Sector
- Manufacturing
- Reference
- FaT-ocds-h6vhtk-02be28
- Published
- 2022-01-14
Tender summary
Potential periods of call-offs under the framework agreement: Transition (Everolimus) CESW: 1 March 2022 – 30 September 2023 (19 months) LSNE: 1 March 2022 – 31 January 2023 (11 months) NWLN: 1 March 2022 – 31 January 2023 (11 months) Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 (27 months) Hospital Only Products CESW: 1 February 2022 – 30 September 2023 (20 months) LSNE: 1 February 2022 – 31 May 2024 (28 months) NWLN: 1 February 2022 – 31 January 2023 (12 months)
This is a public summary of a procurement notice. Dates and status reflect the notice held by BidScout; check the full notice before bidding.
Full tender details have a three-minute guest preview for open opportunities. AI insights require registration.
Register for full access